sabcs 2013: neoaltto, breast cancer with pathologic complete response, event-free & overall survival
Published 10 years ago • 566 plays • Length 9:01Download video MP4
Download video MP3
Similar videos
-
1:45
association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...
-
3:52
an introduction to the 2013 san antonio breast cancer symposium: neo-altto study
-
3:37
sabcs 2013: neoadjuvant focus
-
17:57
martine piccart-gebhart: survival follow-up analysis of the neoaltto study (big 1-06)
-
2:25
reducing risk in residual breast cancer
-
3:09
overall survival results from monaleesa-3 study on ribociclib plus fulvestrant in advanced breas...
-
3:13
mona's story: battling advanced breast cancer
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
3:45
old vid 1
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
10:05
piii trial supports current standard 12-month adjuvant trastuzumab for her2-positive breast cancer
-
6:17
sabcs11 pc josé baselga dual her2 blockade significantly extends progression free survival
-
9:13
substituting trastuzumab emtansine for adjuvant trastuzumab improved idfs for breast cancer pati...
-
34:38
sabcs 2013: triple-negative therapy and chemotherapy
-
7:40
adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
2:03
preoperative management of operable ct3 cn1 luminal breast cancer: upfront neoadjuvant chemotherapy
-
7:18
molecular evolution of breast cancer during neoadjuvant chemotherapy